Filing Details

Accession Number:
0001127602-22-022299
Form Type:
4
Zero Holdings:
No
Publication Time:
2022-09-12 16:27:02
Reporting Period:
2022-09-12
Accepted Time:
2022-09-12 16:27:02
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1061983 Cytokinetics Inc CYTK Pharmaceutical Preparations (2834) 943291317
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1226488 T John Henderson 350 Oyster Point Blvd
South San Francisco CA 94080
Yes No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2022-09-12 7,250 $4.02 31,299 No 4 M Direct
Common Stock Disposition 2022-09-12 7,250 $54.94 24,049 No 4 S Direct
Common Stock Acquisiton 2022-09-12 7,250 $4.02 31,299 No 4 M Direct
Common Stock Disposition 2022-09-12 7,250 $54.95 24,049 No 4 S Direct
Common Stock Acquisiton 2022-09-12 7,259 $4.02 31,308 No 4 M Direct
Common Stock Disposition 2022-09-12 7,259 $54.94 24,049 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
No 4 M Direct
No 4 S Direct
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Non-Qualified Stock Option (Right to Buy) Disposition 2022-09-12 7,250 $0.00 7,250 $4.02
Common Stock Non-Qualified Stock Option (Right to Buy) Disposition 2022-09-12 7,250 $0.00 7,250 $4.02
Common Stock Non-Qualified Stock Option (Right to Buy) Disposition 2022-09-12 7,259 $0.00 7,259 $4.02
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
14,509 2013-02-02 2023-01-02 No 4 M Direct
7,259 2013-02-02 2023-01-02 No 4 M Direct
0 2013-02-02 2023-01-02 No 4 M Direct
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Common Stock 83 Indirect by Spouse
Footnotes
  1. Transaction effected pursuant to a 10b5-1 plan meeting the requirements of Rule 10b5-1(c) under the Exchange Act entered into by the Reporting Person on August 11, 2022.